A detailed history of Baker Bros. Advisors LP transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Baker Bros. Advisors LP holds 9,399,960 shares of BCYC stock, worth $213 Million. This represents 2.53% of its overall portfolio holdings.

Number of Shares
9,399,960
Previous 4,942,823 90.17%
Holding current value
$213 Million
Previous $123 Million 54.58%
% of portfolio
2.53%
Previous 1.56%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$20.02 - $24.69 $89.2 Million - $110 Million
4,457,137 Added 90.17%
9,399,960 $190 Million
Q1 2024

May 15, 2024

BUY
$16.75 - $26.1 $52.8 Million - $82.3 Million
3,152,433 Added 176.08%
4,942,823 $123 Million
Q4 2023

Feb 14, 2024

BUY
$13.29 - $22.2 $12.6 Million - $21 Million
946,576 Added 112.18%
1,790,390 $32.4 Million
Q3 2022

Nov 14, 2022

BUY
$17.49 - $28.44 $14.8 Million - $24 Million
843,814 New
843,814 $19.6 Million

Others Institutions Holding BCYC

About BICYCLE THERAPEUTICS plc


  • Ticker BCYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,676,100
  • Market Cap $674M
  • Description
  • Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...
More about BCYC
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.